SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Facade of Novo Nordisk's office in Fremont, California
GLP-1
Novo’s Semaglutide Potentially Linked to Higher Risk of Suicidal Thoughts: Study
Patients taking Novo Nordisk’s blockbuster GLP-1 drug appear to be more likely to harbor thoughts of suicide or self-harm, especially if they are already suffering from anxiety or depressive disorders, according to a new study.
August 21, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Regeneron logo on a light brown building
Approvals
FDA Denies Approval of Regeneron’s Linvoseltamab for Multiple Myeloma, Cites Third-Party Issues
The regulator’s Complete Response Letter flagged problems at a third-party fill/finish site, which Regeneron says it has already addressed. The manufacturing facility is currently awaiting reinspection.
August 21, 2024
 · 
2 min read
 · 
Tristan Manalac
U.S. and Chinese flags in concrete, broken in the middle
China
House Lawmakers Raise Alarm About US Biopharma Companies Working With Chinese Military on Trials
In a letter to FDA Commissioner Robert Califf, a House committee flagged several U.S. companies—including Eli Lilly and Pfizer—that have allegedly worked with the People’s Liberation Army on clinical trials in Xinjiang, raising ethical and intellectual property concerns.
August 21, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcast
New IRA Drug Prices, Lots of Layoffs, Moderna’s Vaccine Opportunity
Last week, the Biden administration revealed the first drug prices negotiated under the Inflation Reduction Act; Lykos, Grail and others make substantial staffing cuts, and Pfizer/BioNTech see mixed results for their COVID/flu vaccine.
August 21, 2024
 · 
1 min read
 · 
Heather McKenzie
Illustration of hand holding $100 bills spread out
Compensation
Pay Range Transparency: New Law Could Help Massachusetts Biopharma Industry
Massachusetts’ new salary range transparency law can be a tool for companies looking to attract biopharma professionals while also helping candidates and current employees improve their job searches and salaries, according to two experts.
August 21, 2024
 · 
5 min read
 · 
Angela Gabriel
Illustration of a bald eagle swooping down on a factory
BIOSECURE Act
US Manufacturing Unprepared for BIOSECURE Act’s Repercussions
As the pharma industry awaits congressional action on the bill, gaping holes in the domestic drug manufacturing ecosystem have never been clearer.
August 21, 2024
 · 
5 min read
 · 
Keerthi Vedantam
illustration of hands reaching for a semaglutide injector over an image of the Earth
GLP-1
As Novo and Lilly Focus on a Few Big Markets, Sanofi Seeks Global Reach for Diabetes GLP-1 Drug
Experts say Novo Nordisk and Eli Lilly’s GLP-1 drugs are unlikely to reach more countries in the near term, but Sanofi’s diabetes treatment has gained ground globally.
August 21, 2024
 · 
5 min read
 · 
Patience Asanga
News
Video Recap - Regulatory Agility: The Intersection of AI and QARA
August 20, 2024
 · 
1 min read
 · 
BioSpace Insights
Johnson & Johnson's business center in Switzerland
FDA
J&J’s Rybrevant Combo Gets FDA Approval as First Chemo-Free Treatment for NSCLC
Johnson & Johnson announced Tuesday that the FDA has approved Rybrevant with Lazcluze as a first-line chemotherapy-free treatment for patients with EGFR-mutated non-small cell lung cancer.
August 20, 2024
 · 
1 min read
 · 
Kate Goodwin
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS